ArticleAnnals of surgical oncology2026
Multigene Germline Testing in Patients with DCIS vs Invasive Breast Cancer in a Large, Integrated Health Care System.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdentification of germline pathogenic (PV) and likely pathogenic variants (LPV) can inform patients of their risk for breast cancer, empowering them to utilize risk-reducing strategies. National guidelines for germline testing are the same for invasive breast cancer (IBC) and ductal carcinoma in situ (DCIS); however, data on how testing and results compare for patients with DCIS versus IBC are limited.
methodsThis retrospective cohort study of multigene panel germline testing compared women with DCIS versus stage I-III IBC diagnosed between September 2019 through September 2022 at Kaiser Permanente Northern California.
resultsOf the 1490 patients with DCIS and 8474 patients with IBC, the percentage of patients who underwent genetic testing was higher in those with IBC (38%, n = 3223) than in those with DCIS (28.5%, n = 424) (p < 0.00001). Among tested patients, the prevalence of PV/LPV in any breast cancer-related (BCR) gene was higher for IBC (9.1%) than for DCIS (6.1%) (p=0.041). The prevalence of PV/LPV in moderate-risk genes was similar (3.4% in IBC and 3.3% in DCIS; p=0.8798), whereas the prevalence in high-risk genes was higher for patients with IBC (5.8%) than for those with DCIS (3.1%) (p =0.0189).
conclusionsAlthough the prevalence of PV/LPV in high-risk BCR genes was lower in DCIS than in IBC, the prevalence of PV/LPV was similar in moderate-risk BCR genes. Our study supports continuing the same genetic testing guidelines for DCIS and IBC since carrying a PV/LPV in a moderate-risk BCR gene will affect treatment and surveillance decisions.
Indexed as
Identifiers
41530599What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.